logo

Atara Biotherapeutics, Inc. (ATRA)



Trade ATRA now with
  Date
  Headline
6/17/2020 8:51:10 AM Atara : First Patient Enrolled In Study Of Allogeneic T-cell Therapy ATA188 In Progressive Forms Of MS
5/27/2020 1:20:44 AM Atara Biotherapeutics Reports Pricing Of $175.5 Mln Public Offering
5/26/2020 7:09:53 AM Atara Biotherapeutics Presents Addl Safety And Efficacy Data From Phase 1 Study Of ATA188
5/15/2020 9:44:32 AM Atara Biotherapeutics Announces Presentation Of Late-Breaking Preclinical Data On ATA2271
4/22/2020 8:56:43 PM Atara Biotherapeutics Reports Inducement Grants
4/2/2020 8:47:03 AM Atara Biotherapeutics Says Remains On Track To Initiate A Tab-cel BLA Submission For Patients With EBV+ PTLD In H2
2/5/2020 8:35:41 AM Atara Biotherapeutics Names Kristin Yarema As Chief Commercial Officer
9/9/2019 8:14:41 AM Atara To Present Efficacy, Addl Safety Results From Phase 1 Study Of ATA188
7/19/2019 12:42:02 AM Atara Biotherapeutics Prices Public Offering Of 6.87 Mln Shares At $15.28/Shr
7/16/2019 7:03:12 AM Atara Biotherapeutics Announces Plan To Initiate Tab-cel FDA BLA Submission Next Year
6/29/2019 9:56:25 AM Atara Presents Initial ATA188 Phase 1 Safety Results For Patients With Progressive MS At 5th Congress Of EAN
5/29/2019 6:58:07 AM Wedbush Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
4/1/2019 7:19:33 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
2/26/2019 7:42:43 AM Atara Biotherapeutics Q4 Net Loss $80.0 Mln Or $1.75/Shr Vs Loss $35.3 Mln Or $1.15/Shr Last Year
1/3/2019 7:42:16 AM Atara Biotherapeutics Says Isaac Ciechanover Plans To Step Down As President And CEO
1/3/2019 7:33:31 AM Atara Exclusively Licenses Rights To A Mesothelin-targeted CAR T Immunotherapy For Solid Tumors From MSK